| Year |
Citation |
Score |
| 2013 |
Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Molecular Cancer Therapeutics. 12: 1701-14. PMID 23804705 DOI: 10.1158/1535-7163.Mct-12-0893 |
0.534 |
|
| 2012 |
Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Briefings in Functional Genomics. 11: 300-10. PMID 22753777 DOI: 10.1093/Bfgp/Els022 |
0.47 |
|
| 2011 |
Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS. MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. Plos One. 6: e17165. PMID 21365009 DOI: 10.1371/Journal.Pone.0017165 |
0.446 |
|
| 2010 |
Bromberg-White J, Lee CS, Duesbery N. Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins. 2: 1038-53. PMID 22069624 DOI: 10.3390/Toxins2051038 |
0.445 |
|
| 2010 |
Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma Molecular Cancer Therapeutics. 9: 190-201. PMID 20053778 DOI: 10.1158/1535-7163.MCT-09-0694 |
0.393 |
|
| 2009 |
Alfano RW, Leppla SH, Liu S, Bugge TH, Meininger CJ, Lairmore TC, Mulne AF, Davis SH, Duesbery NS, Frankel AE. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis Molecular Cancer Research. 7: 452-461. PMID 19372576 DOI: 10.1158/1541-7786.MCR-08-0451 |
0.46 |
|
| 2009 |
Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH. Pathophysiology of anthrax. Frontiers in Bioscience (Landmark Edition). 14: 4516-24. PMID 19273366 DOI: 10.2741/3544 |
0.303 |
|
| 2008 |
Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molecular Cancer Therapeutics. 7: 1218-26. PMID 18483309 DOI: 10.1158/1535-7163.Mct-08-0024 |
0.454 |
|
| 2008 |
Bromberg-White JL, Duesbery NS. Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways. Methods in Enzymology. 438: 355-65. PMID 18413261 DOI: 10.1016/S0076-6879(07)38025-7 |
0.344 |
|
| 2008 |
Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Molecular Cancer Therapeutics. 7: 648-58. PMID 18319331 DOI: 10.1158/1535-7163.MCT-07-2229 |
0.511 |
|
| 2008 |
Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle (Georgetown, Tex.). 7: 745-9. PMID 18245947 DOI: 10.4161/cc.7.6.5627 |
0.318 |
|
| 2008 |
Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, Teh BT. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Research. 68: 81-8. PMID 18172299 DOI: 10.1158/0008-5472.CAN-07-5311 |
0.536 |
|
| 2007 |
Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5926-34. PMID 17908989 DOI: 10.1158/1078-0432.Ccr-07-0732 |
0.416 |
|
| 2007 |
Young JJ, Bromberg-White JL, Zylstra C, Church JT, Boguslawski E, Resau JH, Williams BO, Duesbery NS. LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. Plos Pathogens. 3: e27. PMID 17335347 DOI: 10.1371/Journal.Ppat.0030027 |
0.32 |
|
| 2006 |
Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7437-43. PMID 17189417 DOI: 10.1158/1078-0432.Ccr-06-2019 |
0.53 |
|
| 2006 |
Duesbery N, Vande Woude G. BRAF and MEK mutations make a late entrance. Science's Stke : Signal Transduction Knowledge Environment. 2006: pe15. PMID 16569817 DOI: 10.1126/Stke.3282006Pe15 |
0.451 |
|
| 2005 |
Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Molecular Cancer Therapeutics. 4: 1303-10. PMID 16170021 DOI: 10.1158/1535-7163.Mct-05-0145 |
0.494 |
|
| 2004 |
Liang X, Young JJ, Boone SA, Waugh DS, Duesbery NS. Involvement of domain II in toxicity of anthrax lethal factor. The Journal of Biological Chemistry. 279: 52473-8. PMID 15465830 DOI: 10.1074/jbc.M409105200 |
0.417 |
|
| 2003 |
Perdiguero E, Pillaire MJ, Bodart JF, Hennersdorf F, Frödin M, Duesbery NS, Alonso G, Nebreda AR. Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C. The Embo Journal. 22: 5746-56. PMID 14592973 DOI: 10.1093/emboj/cdg559 |
0.521 |
|
| 2003 |
Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF. Novel protein targeted therapy of metastatic melanoma. Current Pharmaceutical Design. 9: 2060-6. PMID 14552326 DOI: 10.2174/1381612033454162 |
0.42 |
|
| 2003 |
Chopra AP, Boone SA, Liang X, Duesbery NS. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. The Journal of Biological Chemistry. 278: 9402-6. PMID 12522135 DOI: 10.1074/jbc.M211262200 |
0.482 |
|
| 2002 |
Bodart JF, Gutierrez DV, Nebreda AR, Buckner BD, Resau JR, Duesbery NS. Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes. Developmental Biology. 245: 348-61. PMID 11977986 DOI: 10.1006/dbio.2002.0647 |
0.444 |
|
| 2002 |
Duesbery NS, Vande Woude GF. Developmental biology: an arresting activity. Nature. 416: 804-5. PMID 11976667 DOI: 10.1038/416804a |
0.359 |
|
| 2002 |
Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America. 99: 3052-7. PMID 11867750 DOI: 10.1073/Pnas.052707699 |
0.579 |
|
| 2002 |
Koo H, Duesbery NS, Vande Woude GF. Anthrax Toxins, Mitogen-Activated Protein Kinase Pathway, and Melanoma Treatment Directions in Science. 1: 123-126. DOI: 10.1100/tsw.2002.911 |
0.526 |
|
| 2001 |
Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Vande Woude GF. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proceedings of the National Academy of Sciences of the United States of America. 98: 4089-94. PMID 11259649 DOI: 10.1073/PNAS.061031898 |
0.424 |
|
| 1999 |
Duesbery NS, Vande Woude GF. Anthrax toxins. Cellular and Molecular Life Sciences : Cmls. 55: 1599-609. PMID 10526577 DOI: 10.1007/s000180050399 |
0.519 |
|
| Show low-probability matches. |